XenoPort to Present at the Credit Suisse Healthcare Conference

  XenoPort to Present at the Credit Suisse Healthcare Conference

2012 Credit Suisse Healthcare Conference

Business Wire

SANTA CLARA, Calif. -- November 01, 2012

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via
the World Wide Web to its presentation at the 2012 Credit Suisse Healthcare
Conference. The live presentation will occur at 1:00 p.m. Pacific Time (4:00
p.m. Eastern Time) on Wednesday, November 14, 2012. A replay of the
presentation will also be available.

To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Web site at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may be
necessary to listen to the Webcast.

A replay of the Webcast can be accessed for a minimum of one month and will be
available approximately 24 hours after the live presentation.

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. Horizant® (gabapentin
enacarbil) Extended-Release Tablets is approved in the United States for the
treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults
and for the management of postherpetic neuralgia in adults. GlaxoSmithKline
holds commercialization rights and certain development rights for Horizant in
the United States. Regnite® (gabapentin enacarbil) Extended-Release Tablets is
approved for the treatment of RLS in Japan. Astellas Pharma Inc. holds all
development and commercialization rights for Regnite in Japan and five other
Asian countries. XenoPort holds all other world-wide rights and has
co-promotion and certain development rights to gabapentin enacarbil in the
United States. XenoPort's pipeline of product candidates includes potential
treatments for patients with spasticity, Parkinson's disease and
relapsing-remitting multiple sclerosis.

To learn more about XenoPort, please visit the Web site at www.XenoPort.com.

XENOPORT and Regnite are registered trademarks of XenoPort, Inc.

Horizant is a registered U.S. trademark of GlaxoSmithKline.

XNPT2G

Contact:

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
 
Press spacebar to pause and continue. Press esc to stop.